Sign in to view content

Abicipar Phase 2 MAPLE Trial Supports Improved Safety for Patients with nAMD Following a Modified Manufacturing Process

Raj K. Maturi, MD

Video
Published 2019

Related

Patients Ultra-Responsive to Ranibizumab (RBZ): Rates of >4-Step Improvement in Diabetic Retinopathy Severity in DRCR.net Protocol S
Allen Chiang, MD, FASRS
Updates from the Field
2019
Intravitreal Bevacizumab vs. Bevacizumab with Dexamethasone for the Treatment of Exudative Age-Related Macular Degeneration
Reda Issa, MD
On Demand Cases, Courses, and Papers
2019
A Comparison of the Anatomical Efficacy of Brolucizumab Versus Aflibercept in nAMD Patients: Matched 16-Week Results From the HAWK and HARRIER Studies
Pravin U. Dugel, MD
Annual Meeting Talks
2018

Category: AMD-Neovascular

See more